Acceptance of cpp-1x (dfmo) abstract for poster presentation at endocrine society meeting

Minneapolis, april 06, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract about cpp-1x (also known as dfmo or eflornithine) research, has been accepted for poster presentation at the endocrine society meeting, which will be held june 15-18, 2023.
PBLA Ratings Summary
PBLA Quant Ranking